Drugs / Hetrombopag
Hetrombopag
also known as
Hetrombopag Olamine · Hetrombopag (HPAG) · Hetrombopag Olamine Tablets · HPAG · SHR8735 · SHR8735 Olamine
Trials 41 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT04701216 | Feb → Jul 2021 | — | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05088642 | Sep → Dec 2020 | aplastic anemia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04688008 | Sep → Oct 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05088343 | Sep 2020 → Jan 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05088174 | Sep → Oct 2020 | aplastic anemia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03977805 | May → Jun 2019 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02614846 | Aug 2015 → Mar 2016 | autoimmune thrombocytopenic purpura | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02403440 | Apr 2014 → Apr 2015 | autoimmune thrombocytopenic purpura | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02409394 | Mar → Apr 2014 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01830660 | Apr 2012 → Jun 2013 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03557099 | Jun 2018 → Oct 2019 | aplastic anemia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 216 trials | ||||||
| Phase 2 | NCT07523009 | Jun 2026 → Dec 2028 | aplastic anemia | Peking Union Medical College Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT07647029 | May 2026 → Feb 2028 expected | chemotherapy-induced toxicity | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07408648 | Apr 2026 → Apr 2027 expected | thrombocytopenia | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07558434 | Apr 2026 → Dec 2028 expected | aplastic anemia | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07252375 | Nov 2025 → May 2028 expected | nasopharyngeal carcinoma, thrombocytopenia | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07101627 | Aug 2025 → Apr 2027 expected | lung cancer | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07010237 | Feb 2025 → Dec 2028 expected | aplastic anemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT07492693 | Oct 2024 → Jul 2026 overdue | chemotherapy-induced toxicity | Changhai Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06099925 | Oct 2023 → Sep 2025 | thrombocytopenia | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT06036966 | Sep 2023 → Jul 2025 | thrombocytopenia | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05943691 | Sep 2023 → Jul 2024 | autoimmune thrombocytopenia | Shandong University | Unknown | No outcome recorded |
| Phase 2 | NCT05969158 | Sep 2023 → May 2025 | thrombocytopenia | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05394285 | Sep 2022 → Jun 2025 | breast cancer | Henan Cancer Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05442632 | Jul 2022 → Dec 2025 | liver disorder | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05392647 | Jul 2022 → Jul 2024 | myelodysplastic syndrome | Tongji Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06433830 | May 2022 → May 2025 | thrombocytopenia | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT05018936 | Oct 2021 → Oct 2023 | aplastic anemia | Peking Union Medical College Hospital | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT05024877 | Oct 2021 → Oct 2023 | myelodysplastic syndrome | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT04915482 | Jun 2021 → Jan 2025 | Evans syndrome, connective tissue disorder | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT05864014 | Apr 2023 → Mar 2025 overdue | thrombocytopenia | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05261646 | Apr 2022 → Mar 2025 | thrombocytopenia | Jiangsu HengRui Medicine Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 3 | NCT04737850 | Mar 2021 → Dec 2024 | autoimmune thrombocytopenia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03976882 | Nov 2019 → Feb 2023 | thrombocytopenia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04961710 | Sep 2019 → Nov 2024 overdue | idiopathic aplastic anemia | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03825744 | Mar 2019 → Jul 2024 | aplastic anemia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03222843 | Jun 2017 → Nov 2019 | autoimmune thrombocytopenic purpura | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06562738 | Jun 2024 → Jan 2025 overdue | thrombocytopenia | The Third People's Hospital of Chengdu | Recruiting | No outcome recorded |
| Phase 4 | NCT05311930 | May 2022 → Dec 2024 | autoimmune thrombocytopenia | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06818916 | Jun 2024 → Apr 2027 expected | neuroblastoma | Beijing Children's Hospital | Recruiting | No outcome recorded |
| — | NCT05727917 | Jan 2023 → May 2024 | disease related to hematopoietic stem cell transplant, hematologic disorder | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07669675 Background | Jul 2026 → Dec 2027 expected | autoimmune thrombocytopenia | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07334093 Comparator | Jan 2026 → Nov 2027 expected | acquired thrombocytopenia | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05718856 Comparator | Feb 2023 → May 2025 | primary thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 45 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hetrombopag | “Oral Hetrombopag Olamine Tablets will be initiated at a daily dose of 5 mg (initial dose) on Day 1 (D1) of each chemotherapy cycle, and administered continuously until the...” NCT07252375 ↗42“Hetrombopag is given at an initial dose of 7.5 mg once daily for 14 days; eltrombopag is given at an initial dose of 75 mg once daily for 14 days” NCT07669675 ↗ “Three TPO-RAs could be used in this study, including eltrombopag, hetrombopag and avatrombopag.” NCT05718856 ↗ “The starting dose of hetrombopag is 5.0-7.5mg once daily.” NCT04915482 ↗ “Hetrombopag 7.5mg/d, increased by 2.5mg every two weeks” NCT07558434 ↗ “hetrombopag 7.5mg/d, maximum dose 15mg/d” NCT07523009 ↗ |
| Known as | Hetrombopag (HPAG) | “Hetrombopag (HPAG)” NCT07558434 ↗ |
| Known as | Hetrombopag Olamine | “A Phase I, Randomized, Placebo-controlled, Ascending Single And Multiple Oral Dose Study To Investigate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of...” NCT01830660 ↗3“Drug: Hetrombopag Olamine” NCT03557099 ↗ “Drug: Hetrombopag Olamine” NCT02614846 ↗ “Drug: Hetrombopag Olamine” NCT03222843 ↗ |
| Known as | Hetrombopag Olamine Tablets | “Oral Hetrombopag Olamine Tablets will be initiated at a daily dose of 5 mg (initial dose) on Day 1 (D1) of each chemotherapy cycle, and administered continuously until the...” NCT07252375 ↗ |
| Known as | HPAG | “eltrombopag (EPAG)/hetrombopag (HPAG)” NCT07523009 ↗ |
| Known as | SHR8735 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04701216 ↗ |
| Known as | SHR8735 Olamine | “A Phase I, Randomized, Placebo-controlled, Ascending Single And Multiple Oral Dose Study To Investigate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of...” NCT01830660 ↗ |
| Action | Activate | “Hetrombopag is a novel, small-molecule thrombopoietin receptor agonist” PMID 32865293 ↗ Oct 2020 |
| Modality | Small molecule | “Hetrombopag is a novel, small-molecule thrombopoietin receptor agonist” PMID 32865293 ↗ Oct 2020 |
| Route | Oral | “hetrombopag either at 2.5,5,10,20,30 or 40mg, p.o. once daily” NCT01830660 ↗ |